Want to see SABS full AI Analyst Report?

SAB Biotherapeutics (SABS) Price & Analysis

330 Followers

SABS Stock Chart & Stats

$3.88

-$0.07(-1.99%)

At close: Jul 27 4:00 PM EDT

$3.88

-$0.07(-1.99%)

Day’s Range― - ―

52-Week Range$2.10 - $5.15

Previous Close$3.44

Volume609.58K

Average Volume (3M)666.53K

Market Cap

$230.20M

Enterprise Value$213.54M

Total Cash (Recent Filing)$102.63M

Total Debt (Recent Filing)$5.13M

Price to Earnings (P/E)0.7

Beta1.07

Next Earnings

Nov 17, 2026

EPS Estimate

-0.28

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)3.57

Shares Outstanding90,986,370

10 Day Avg. Volume765,713

30 Day Avg. Volume666,533

Financial Highlights & Ratios

PEG Ratio-0.16

Price to Book (P/B)0.48

Price to Sales (P/S)0.00

P/FCF Ratio-1.58

Enterprise Value/Market Cap0.93

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-93.60

Enterprise Value/Ebitda-22.65

Forecast

1Y Price Target

$12.67

Price Target Upside226.46% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)-1.2

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Proprietary Antibody PlatformSAB’s proprietary transchromosomic bovine platform is designed to generate fully human polyclonal antibodies at scale. This provides a differentiated technology base that can support multiple infectious-disease and serious-condition programs, creating potential platform leverage beyond a single drug candidate.

Low Financial LeverageVery low leverage and materially increased equity and assets provide financial flexibility relative to a highly indebted biotechnology company. This stronger capital structure may give SAB more room to continue development activities while pursuing partnerships or other funding to support its pipeline.

Regulatory Progress And Clinical BreadthFast Track designation recognizes SAB-142’s potential to address an unmet medical need and may support more efficient regulatory interaction. The Phase 2b SAFEGUARD and investigator-led Phase 3 PRISE-hATG studies also broaden clinical validation across newly diagnosed type 1 diabetes patients.

Bears Say

Revenue CollapseThe collapse from substantial 2021 revenue to effectively zero in 2025 and TTM indicates that SAB currently lacks a dependable revenue engine. Without recovery through partnerships, funding, or commercialization, the company has limited internally generated resources to sustain long-duration clinical development.

Persistent Operating Losses And Cash BurnLarge operating losses and sustained negative operating and free cash flow show that SAB is consuming capital to advance its programs. Continued spending at this level can require additional financing or cost reductions, while also limiting the company’s ability to fund development independently.

Dependence On Partnerships And Non-dilutive FundingSAB’s clinical-stage model depends primarily on collaboration revenue, grants, and milestone-based consideration rather than recurring product sales. This makes financial progress dependent on securing partners and achieving development or regulatory milestones before a durable commercial revenue base can emerge.

SAB Biotherapeutics News

SAB Biotherapeutics granted Fast Track designation for SAB-142

SAB Biotherapeutics (SABS) announced that the FDA has granted Fast Track designation to SAB-142, a potentially disease-modifying immunotherapy...

6d ago

SABS

SAB Biotherapeutics Wins FDA Fast Track for SAB-142

SAB Biotherapeutics ( ($SABS) ) just unveiled an update. On October 13, 2026, SAB Biotherapeutics announced that the...

6d ago

SABS

SAB Biotherapeutics advances SAB-142 Type 1 diabetes trial

The latest announcement is out from SAB Biotherapeutics ( ($SABS) ). On July 7, 2026, SAB Biotherapeutics and...

3M ago

SABS

SAB Biotherapeutics initiated with an Overweight at Barclays

Barclays analyst Eliana Merle initiated coverage of SAB Biotherapeutics (SABS) with an Overweight rating and $13 price target...

4M ago

SABS

SAB Biotherapeutics Shareholders Back Board and Auditor

The latest update is out from SAB Biotherapeutics ( ($SABS) ). On June 18, 2026, SAB Biotherapeutics held...

4M ago

SABS

SAB Biotherapeutics Reaffirmed Buy/High Risk on Regulatory Derisking, Positive SAB-142 Data and Unchanged $11 Price Target

SAB Biotherapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Samantha Semenkow from...

4M ago

SABS

SAB Biotherapeutics: Buy Rating Reiterated as Tzield Approval De-Risks SAB-142, $10 Price Target Maintained

In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on SAB Biotherapeutics, with...

4M ago

SABS

SAB Biotherapeutics initiated with a Buy at Citi

Citi initiated coverage of SAB Biotherapeutics (SABS) with a Buy rating and $11 price target The firm says...

5M ago

SABS

SAB Biotherapeutics initiated with a Buy at Jefferies

Jefferies initiated coverage of SAB Biotherapeutics (SABS) with a Buy rating and $11 price target The company’s lead...

5M ago

SABS

SAB Biotherapeutics price target raised to $10 from $7 at H.C. Wainwright

H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on SAB Biotherapeutics (SABS) to $10 from $7...

5M ago

SABS

SAB Biotherapeutics Signs Manufacturing Pact for SAB-142

An announcement from SAB Biotherapeutics ( ($SABS) ) is now available. On April 28, 2026, SAB Biotherapeutics entered...

6M ago

SABS

Emergent BioSolutions enters SAB-142 development pact with SAB Biotherapeutics

Emergent BioSolutions (EBS) announced a multi-year agreement with SAB Biotherapeutics (SABS) to support the process development and manufacturing...

6M ago

EBS

SABS

Buy Rating on SABS Driven by SAB-142’s Differentiated T1D Mechanism, Durable C‑Peptide Preservation, and Pivotal SAFEGUARD Catalyst

In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on SAB Biotherapeutics, with...

6M ago

SABS

SAB Biotherapeutics Highlights Positive Phase 1 SAB-142 Results

An update from SAB Biotherapeutics ( ($SABS) ) is now available. On April 22, 2026, SAB BIO presented...

6M ago

SABS

SABS FAQ

What was SAB Biotherapeutics’s price range in the past 12 months?

SAB Biotherapeutics lowest stock price was $2.10 and its highest was $5.15 in the past 12 months.

What is SAB Biotherapeutics’s market cap?

SAB Biotherapeutics’s market cap is $230.20M.

When is SAB Biotherapeutics’s upcoming earnings report date?

SAB Biotherapeutics’s upcoming earnings report date is Nov 17, 2026 which is in 29 days.

How were SAB Biotherapeutics’s earnings last quarter?

SAB Biotherapeutics released its earnings results on Aug 06, 2026. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.283 by $0.003.

Is SAB Biotherapeutics overvalued?

According to Wall Street analysts SAB Biotherapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does SAB Biotherapeutics pay dividends?

SAB Biotherapeutics does not currently pay dividends.

What is SAB Biotherapeutics’s EPS estimate?

SAB Biotherapeutics’s EPS estimate is -0.28.

How many shares outstanding does SAB Biotherapeutics have?

SAB Biotherapeutics has 90,986,370 shares outstanding.

What happened to SAB Biotherapeutics’s price movement after its last earnings report?

SAB Biotherapeutics reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.283. Following the earnings report the stock price went up 2.122%.

Which hedge fund is a major shareholder of SAB Biotherapeutics?

Currently, no hedge funds are holding shares in SABS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

SAB Biotherapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-6.74%

Trailing 12-Months

Asset Growth

690.62%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

SAB Biotherapeutics

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.

SAB Biotherapeutics (SABS) Earnings & Revenues

Historic Earnings Reports

SABS Earnings Call

Q2 2026

0:00 / 0:00

SABS Stock 12 Month Forecast

Average Price Target

$12.67

▲(226.46% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","4":"$4","8":"$8","12":"$12","16":"$16"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.666666666666666,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4,8,12,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.06,3.9784615384615387,4.896923076923077,5.815384615384616,6.733846153846153,7.6523076923076925,8.570769230769232,9.489230769230769,10.407692307692308,11.326153846153847,12.244615384615384,13.163076923076924,14.081538461538463,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.06,3.798974358974359,4.5379487179487175,5.276923076923077,6.015897435897436,6.754871794871795,7.493846153846153,8.232820512820513,8.971794871794872,9.71076923076923,10.449743589743589,11.18871794871795,11.927692307692308,{"y":12.666666666666666,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.06,3.5938461538461537,4.127692307692308,4.661538461538462,5.195384615384615,5.729230769230769,6.263076923076923,6.796923076923077,7.330769230769231,7.8646153846153855,8.39846153846154,8.932307692307692,9.466153846153846,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.98,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.25,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.79,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.74,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.38,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.07,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.87,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.47,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.44,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.88,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.57,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.7,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >